tiprankstipranks
Trending News
More News >

D.Western Therapeutics Extends Cataract Research Partnership

Story Highlights
D.Western Therapeutics Extends Cataract Research Partnership

Don’t Miss TipRanks’ Half-Year Sale

D.Western Therapeutics Institute ( (JP:4576) ) just unveiled an announcement.

D.Western Therapeutics Institute, Inc. has extended its joint research agreement with the University of Fukui to develop novel therapeutic and preventive drugs for cataracts. This collaboration aims to create an eye drop formulation as an alternative to cataract surgery, offering a broader range of treatment options and reducing the burden on patients. The extension of this agreement signifies the company’s commitment to advancing ophthalmological research, although it will not affect the earnings forecast for the fiscal year ending December 2025.

More about D.Western Therapeutics Institute

D.Western Therapeutics Institute, Inc. operates in the ophthalmology industry, focusing on drug discovery to develop new therapeutic candidates. The company is dedicated to creating innovative treatments for eye conditions, particularly cataracts, through early detection, prevention, and treatment options.

Average Trading Volume: 2,903,641

Technical Sentiment Signal: Strong Sell

Current Market Cap: Yen4.62B

For a thorough assessment of 4576 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1